Particle-Driven Radiogenomics for Quantifying Tumor Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radiogenomics technologies suffer from size-dependent limitations in evaluating tumor efficacy, particularly for non-cytotoxic treatments, and rely heavily on qualitative visual analysis, failing to accurately quantify treatment response and tumor progression.
Innovation Solution
Particle-driven radiogenomics systems that combine structural, functional, and metabolic imaging techniques using nanoparticle-based species to extract quantitative multi-dimensional data, linking intratumoral and interstitial nanoparticle distributions with molecular markers for improved treatment prediction and monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If size-based tumor evaluation methods are used, then standardization is maintained, but accuracy in reflecting tumor biology deteriorates
Solution Approach 1:
The patent transitions from size-based parameters to molecular and functional parameters (nanoparticle distribution, metabolic activity, perfusion characteristics) to assess tumor biology. This parameter change enables accurate reflection of tumor heterogeneity and treatment response while maintaining systematic evaluation through multi-parametric imaging protocols.
Solution Approach 2:
The patent employs composite imaging approaches that integrate multiple imaging modalities (PET, MRI, CT) with nanoparticle tracers to create a comprehensive assessment system. This composite approach combines structural, functional, and molecular information to achieve accurate tumor biology assessment without relying on a single complex technique.
2Measurement precision
If qualitative visual analysis is used, then ease of operation is maintained, but measurement precision deteriorates
Solution Approach 1:
The patent introduces quantitative imaging biomarkers and computational algorithms as intermediaries between the imaging data and clinical interpretation. These intermediaries automatically extract and quantify treatment response metrics from multi-parametric imaging data, providing precise measurements while reducing the complexity of manual analysis through standardized computational pipelines.
Solution Approach 2:
The patent replaces manual qualitative visual analysis with automated computational image processing and quantitative biomarker extraction. This substitution uses computer-based algorithms to objectively measure treatment response and tumor progression, achieving high precision while maintaining operational efficiency through automated workflows.
3Measurement precision
If advanced non-invasive imaging tools are introduced, then measurement precision improves, but device complexity increases
Solution Approach 1:
The patent employs multi-parametric imaging systems that can perform multiple functions using integrated platforms. The same imaging infrastructure (PET/MRI/CT systems) is used to acquire structural, functional, and molecular data, as well as to track nanoparticle distribution and assess treatment response, thereby achieving high measurement precision without proportionally increasing device complexity through functional integration.
Data Source
AI summary
Described herein are particle-driven radiogenomics systems and methods that can be used to identify imaging features for prediction of intratumoral and interstitial nanoparticle distributions in cancers (e.g., in low grade and/or high-grade brain cancers (e.g., gliomas, e.g., primary gliomas)). In certain embodiments, the systems and methods described herein extract and combine quantitative multi-dimensional data generated from structural, functional, and/or metabolic imaging. In certain embodiments, the combined multidimensional data is linked to intratumoral and interstitial nanoparticle distributions. For example, this linked data can be used to determine quantitative functional-metabolic multimodality particle-based imaging features and to predict treatment efficacy. These techniques provide an improved quantitative ability to measure treatment response and determine tumor progressions compared to traditional size-based imaging methods.